BMT CTN 1102 finds significant survival benefit for MDS patients aged 50 to 75 after alloHCT

Ryotaro Nakamura, MD, et al. – In this practice-changing multi-center biologic assignment trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), researchers provide strong evidence that outcomes of allogeneic hematopoietic cell transplantation (alloHCT) among older patients with advanced myelodysplastic syndrome (MDS) are similar to younger patients and result in no worse quality of life (QOL). BMT CTN 1102 is currently published in the Journal of Clinical Oncology, with a corresponding practice change commentary in Cancer.
View Study